Mar 28, 2023, 02:30 pm
Kolkata-based Zinc Oxide manufacturer, JG Chemicals Ltd has received final observation from the capital markets regulator, Securities and Exchange Board of India (SEBI), to raise funds through an initial public offering (IPO). The company had filed preliminary IPO papers with Sebi on January 4, 2023. The IPO consists of a fresh issue of ₹202.50 crore and an offer-for-sale of up to 5.7 million equity shares by its existing shareholders and promoters.
The OFS comprises up to 3.64 million equity shares by Vision Projects and Finvest Private Limited, 1.4 lakh equity shares by Jayanti Commercial Limited, 1.27 million equity shares by Suresh Kumar Jhunjhunwala (HUF), and 6.5 lakh equity shares by Anirudh Jhunjhunwala (HUF).
The company in consultation with merchant bankers to the issue may consider a private placement aggregating up to Rs. 40 crore or a secondary sale by selling shareholders of up to 28,50,000 equity shares or a combination thereof. If such placement is completed, the fresh issue size will be reduced.
JG Chemicals IPO net proceeds
The proceeds from the fresh issue will be used for investment in its material arm BDJ Oxides. The company will use ₹45 crore for repayment of the debt, ₹5.31 crore to set up a research and development center, ₹65 crore for funding its long-term working capital requirement for its subsidiary, and ₹35 crore for its own long-term working capital requirement and general corporate purposes.
Incorporated in the year 2001, by Suresh Jhunjhunwala, JG Chemicals Limited is India’s largest zinc oxide manufacturer in terms of production and revenue. Over the last three years, it marketed and sold its product to over 200 domestic customers and over 50 global customers in more than 10 countries and tyre industry are the largest consumers of its product.
It supplies to 9 out of top 10 global tyre manufacturers and to all of the top 11 tyre manufacturers in India, and also to leading paints manufacturers, footwear players and cosmetics players in India, according to a CARE Report.